Giuseppe D'Onofrio

Dr. Giuseppe D'Onofrio


Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in International Journal of Laboratory Hematology
Verified
Journal Article
Open access
PDF file
John FraterJohn Frater
John Frater
GZGina Zini
Gina Zini
GDGiuseppe D'Onofrio
Giuseppe D'Onofrio
HRHeesun Rogers
Heesun Rogers
The ongoing COVID‐19 pandemic originated in Wuhan, Hubei Province, China, in December 2019. The etiologic agent is a novel coronavirus of presumed zoonotic origin with structural similarity to the viruses responsible for severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). Like SARS and MERS, COVID‐19 infection manifests most frequently with lower respiratory symptoms. A minority of patients progress to acute respiratory distress syndrome/ diffuse alveolar damage. In addition to its central role in the diagnosis of COVID‐19 infection, the clinical laboratory provides critical information to clinicians regarding prognosis, disease course, and response to therapy. The purpose of this review is to (a) provide background context about the origins and course of the pandemic, (b) discuss the laboratory's role in the diagnosis of COVID‐19 infection, (c) summarize the current state of biomarker analysis in COVID‐19 infection, with an emphasis on markers derived from the hematology laboratory, (d) comment on the impact of COVID‐19 on hematology laboratory safety, and (e) describe the impact the pandemic has had on organized national and international educational activities worldwide.

24 August 2021 in International Journal of Laboratory Hematology
Verified
Journal Article
Open access
PDF file
GZGina Zini
Gina Zini
GDGiuseppe D'Onofrio
Giuseppe D'Onofrio
WEWendy N. Erber
Wendy N. Erber
SLSzu‐Hee Lee
Szu‐Hee Lee
YNYutaka Nagai
Yutaka Nagai
I(International Council for Standardization in Hematology (ICSH)
International Council for Standardization in Hematology (ICSH)
In 2012, the International Council for Standardization in Hematology (ICSH) published recommendations for the identification, quantitation, and diagnostic value of schistocytes. In the present review, the impact of these recommendations is evaluated. This work is based on citations in peer‐reviewed papers published since 2012. The first 2012 ICSH Recommendations have also been revised to incorporate newly published data in the literature and current best laboratory practice. Recommended reference ranges have been proposed for healthy adults and full‐term neonates of 1% or less schistocytes. More than 1% of morphologically identified schistocytes on the blood film are considered suspicious for thrombotic microangiopathy. For preterm infants, a normal level of 5% or less is recommended. The fragment red cell count (FRC) generated by some automated hematological analyzers provides a valuable screening tool for the presence of schistocytes. Specifically, the absence of FRCs can be used as a valuable parameter to exclude the presence of schistocytes on the blood film. The validity and usefulness of microscope schistocytes and automated FRCs, respectively, are discussed in the context of the laboratory diagnostic tests used for thrombotic microangiopathies.

10 March 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
HKHanah Kim
Hanah Kim
Mina HurMina Hur
Mina Hur
GDGiuseppe D'Onofrio
Giuseppe D'Onofrio
GZGina Zini
Gina Zini
Digital morphology (DM) analyzers have advanced clinical hematology laboratories by enhancing the efficiency and precision of peripheral blood (PB) smear analysis. This review explores the real-world application of DM analyzers with their benefits and challenges by focusing on PB smear analysis and less common analyses, such as bone marrow (BM) aspirates and body fluids (BFs). DM analyzers may automate blood cell classification and assessment, reduce manual effort, and provide consistent results. However, recognizing rare and dysplastic cells remains challenging due to variable algorithmic performances, which affect diagnostic reliability. The quality of blood film as well as staining techniques significantly influence the accuracy of DM analyzers, and poor-quality samples may lead to errors. In spite of reduced inter-observer variability compared with manual counting, an expert’s review is still needed for complex cases with atypical cells. DM analyzers are less effective in BM aspirates and BF examinations because of their higher complexity and inconsistent sample preparation compared with PB smears. This technology relies heavily on artificial intelligence (AI)-based pre-classifications, which require extensive, well-annotated datasets for improved accuracy. The performance variation across platforms in BM aspirates and rare-cell analysis highlights the need for AI algorithm advancements and DM analysis standardization. Future clinical practice integration will likely combine advanced digital platforms with skilled oversight to enhance diagnostic workflow in hematology laboratories. Ongoing research aims to develop robust and validated AI models for broader clinical applications and to overcome the current limitations of DM analyzers. As technology evolves, DM analyzers are set to transform laboratory efficiency and diagnostic precision in hematology.

28 August 2023 in International Journal of Laboratory Hematology
Verified
Journal Article
Open access
GZGina Zini
Gina Zini
FMFrancesca Mancini
Francesca Mancini
ERElena Rossi
Elena Rossi
SLStefania Landucci
Stefania Landucci
GDGiuseppe D'Onofrio
Giuseppe D'Onofrio
Introduction: Implementing artificial intelligence‐based instruments in hematology laboratories requires evidence of efficiency in classifying pathological cells. In two‐Universities, we assessed the performance of the Mindray® MC‐80 for hematology patients with frequent leukemic and dysplastic cells.Methods: The Mindray MC‐80® locates and pre‐classifies cells in blood films. In a two‐university study, four films were prepared from 591 samples, two each for the analyser MC‐80 and the microscope reference method, using reagents from two different manufacturers. We used Microsoft Excel® statistics for imprecision and distributional inaccuracy and a matrix table model (H20‐A2 CLSI standard) for sensitivity, specificity and predictive value for atypical cells.Results: The results indicate minimal within‐run imprecision (ICSH method) and good intra‐method consistency even on duplicate analysis of 413 samples with a high incidence of hematological abnormalities (r = 0.942 or more, except for basophils, r = 0.841, and reactive lymphocytes, r = 0.847). Distributional inaccuracy was also very low compared to the microscope reference, with a pass rate higher than 80% for pathological cells (except 75.1% for reactive lymphocytes). The primary causes of discrepancy were bizarre shapes of dysplastic neutrophils and inconsistent nomenclature for lymphoma cells. Sensitivity for critical samples containing cells typically absent in circulating blood (immature or malignant) was 98.8% for immature granulocytes, 83.8% for all types of neoplastic cells, 93.6% for reactive lymphocytes and 97.5% for nucleated red blood cells. The negative predictive values of MC‐80 were 98.8% for immature granulocytes, 88.4% for the different types of neoplastic cells, 97.8% for reactive lymphocytes, and 96.9% for nucleated red blood cells.Conclusion: Our study highlights the outstanding diagnostic performance of this artificial intelligence–based blood film analyzer for hematology patients with circulating abnormal cells. We appreciated the morphological harmonization of cells observed on the screen and those seen in the microscope.

12 November 2020 in International Journal of Laboratory Hematology
Verified
Journal Article
Open access
PDF file
RBRobert Bell
Robert Bell
GZGina Zini
Gina Zini
GDGiuseppe D'Onofrio
Giuseppe D'Onofrio
HRHeesun Rogers
Heesun Rogers
YLYi‐Shan Lee
Yi‐Shan Lee
John FraterJohn Frater
John Frater
The ongoing COVID‐19 pandemic has had a profound worldwide impact on the laboratory hematology community. Nevertheless, the pace of COVID‐19 hematology‐related research has continued to accelerate and has established the role of laboratory hematology data for many purposes including disease prognosis and outcome. The purpose of this scoping review was to assess the current state of COVID‐19 laboratory hematology research. A comprehensive search of the literature published between December 1, 2019, and July 3, 2020, was performed, and we analyzed the sources, publication dates, study types, and topics of the retrieved studies. Overall, 402 studies were included in this scoping review. Approximately half of these studies (n = 202, 50.37%) originated in China. Retrospective cohort studies comprised the largest study type (n = 176, 43.89%). Prognosis/ risk factors, epidemiology, and coagulation were the most common topics. The number of studies published per day has increased through the end of May. The studies were heavily biased in favor of papers originating in China and on retrospective clinical studies with limited use of and reporting of laboratory data. Despite the major improvements in our understanding of the role of coagulation, automated hematology, and cell morphology in COVID‐19, there are gaps in the literature, including biosafety and the laboratory role in screening and prevention of COVID‐19. There is a gap in the publication of papers focused on guidelines for the laboratory. Our findings suggest that, despite the large number of publications related to laboratory data and their use in COVID‐19 disease, many areas remain unexplored or under‐reported.

6 October 2022 in British Journal of Haematology
Verified
Journal Article
Open access
GZGina Zini
Gina Zini
GDGiuseppe D'Onofrio
Giuseppe D'Onofrio
Summary: Numerous studies have shown peculiar morphological anomalies in COVID‐19 patients' smears. We searched all the peer‐reviewed scientific publications that explicitly reference the cytomorphological alterations on peripheral blood smears of patients with COVID‐19. We extracted data from sixty‐five publications (case reports, patient group studies, reviews, and erythrocyte morphology studies). The results show that frequent alterations concern the morphology of lymphocytes (large lymphocytes with weakly basophilic cytoplasm, plasmacytoid lymphocytes, large granular lymphocytes). Neutrophils display abnormal nuclei and cytoplasm in a distinctive cytomorphological picture. Besides a left shift in maturation, granulations can be increased (toxic type) or decreased with areas of basophilia. Nuclei are often hyposegmented (pseudo‐Pelger‐Huёt anomaly). Apoptotic or pycnotic cells are not uncommon. Monocytes typically have a large cytoplasm loaded with heterogeneous and coalescing vacuoles. Platelets show large and giant shapes. The presence of erythrocyte fragments and schistocytes is especially evident in the forms of COVID‐19 that are associated with thrombotic microangiopathies. Such atypia of blood cells reflects the generalized activation in severe COVID‐19, which has been demonstrated with immunophenotypic, molecular, genetic, and functional methods. Neutrophils, in particular, are involved in the pathophysiology of hyperinflammation with cytokine storm, which characterizes the most unfavorable evolution.